The first phase 3 clinical trial to successfully confirm mTOR inhibition as a rational strategy in patients who progressed during or after their initial NSAI therapy1
The study investigated the efficacy and safety of AFINITOR (10 mg) in combination with exemestane in HR+, HER2/neu-negative advanced* breast cancer2
Study design and methodology
- Double-blind trial designed to demonstrate superiority of AFINITOR in combination with exemestane over an AI alone2
- Tumor assessments/scans were conducted at baseline and every 6 weeks until disease progression4
- Sensitivity to prior hormonal therapy†
- Presence of visceral disease
†Sensitivity to prior hormonal therapy was defined as either (1) documented clinical benefit (complete response, partial
ABC, advanced breast cancer; AI, aromatase inhibitor; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; CBR, clinical benefit rate; ECOG PS, Eastern Cooperative Oncology Group performance status; HR+, hormone receptor-positive; mTOR, mammalian target of rapamycin; NSAI, nonsteroidal aromatase inhibitor; ORR, objective/overall response rate; OS, overall survival; PFS, progression-free survival; QoL, quality of life; R, randomization.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®: breast cancer. V2.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast. Published March 6, 2014. Accessed July 18, 2014.
- AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2016.
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
- Data on file. Novartis Pharma AG.